Imricor Medical Systems Receives FDA Clearance; Shares Reach Four-Year High
MT Newswires Live
Jan 12
Imricor Medical Systems (ASX:IMR) received 510(k) clearance for its Vision-MR diagnostic catheter under the premarket notification process with the US Food and Drug Administration, according to a Monday filing with the Australian bourse.
The clearance allows the company to commercially market the catheter, which is designed to be used under real-time magnetic resonance imaging guidance, in the US, the filing said
The company expects to obtain multiple regulatory clearances and approvals this year, as per the filing.
Shares rose more than 25% in morning trade on Monday and earlier reached their highest since July 2021.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.